MSD Reports the Acquisition of Modifi Biosciences for $1.33B
Shots:
- MSD has acquired Modifi Biosciences, a company developing direct DNA modification-enabled cancer therapeutics
- Under the terms of the agreement, Modifi Biosciences' shareholders received $30M upfront and are eligible for up to $1.3B in milestone payments
- The acquisition adds a novel class of small molecules targeting a DNA repair protein called MGMT (O6-methylguanine-DNA methyltransferase)
Ref: Globenewswire | Image: MSD & Modifi Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
